Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers

Tamoxifen (TAM) has been used in the treatment of breast cancers and is supplemented with erythropoietin (EPO) to alleviate the cancer-related anemia. The purported deleterious effects caused by the use of EPO with chemotherapeutic agents in the treatment of cancer-related anemia vary across studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Beh, Chaw Yee, How, Chee Wun, Foo, Jhi Biau, Foong, Jia Ning, Selvarajah, Gayathri Thevi, Rasedee, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358988/
https://www.ncbi.nlm.nih.gov/pubmed/28352153
http://dx.doi.org/10.2147/DDDT.S123939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358988/
https://www.ncbi.nlm.nih.gov/pubmed/28352153
http://dx.doi.org/10.2147/DDDT.S123939

Ejemplares similares